PMC:7299399 / 22255-23322 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T102","span":{"begin":61,"end":68},"obj":"Body_part"},{"id":"T103","span":{"begin":104,"end":111},"obj":"Body_part"}],"attributes":[{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T79","span":{"begin":180,"end":190},"obj":"Disease"},{"id":"T80","span":{"begin":355,"end":363},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T225","span":{"begin":268,"end":270},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T226","span":{"begin":537,"end":543},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T227","span":{"begin":547,"end":548},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T228","span":{"begin":590,"end":591},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T229","span":{"begin":688,"end":691},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T230","span":{"begin":729,"end":736},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T231","span":{"begin":757,"end":758},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T232","span":{"begin":918,"end":933},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9544"},{"id":"T233","span":{"begin":948,"end":949},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T234","span":{"begin":986,"end":988},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T235","span":{"begin":1012,"end":1018},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T138","span":{"begin":61,"end":68},"obj":"Chemical"},{"id":"T139","span":{"begin":104,"end":111},"obj":"Chemical"},{"id":"T140","span":{"begin":557,"end":559},"obj":"Chemical"},{"id":"T141","span":{"begin":765,"end":773},"obj":"Chemical"},{"id":"T142","span":{"begin":774,"end":778},"obj":"Chemical"},{"id":"T144","span":{"begin":780,"end":784},"obj":"Chemical"},{"id":"T145","span":{"begin":1030,"end":1032},"obj":"Chemical"}],"attributes":[{"id":"A138","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A141","pred":"chebi_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/CHEBI_28984"},{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_24866"},{"id":"A143","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_74768"},{"id":"A145","pred":"chebi_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T95","span":{"begin":0,"end":756},"obj":"Sentence"},{"id":"T96","span":{"begin":757,"end":1067},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"336","span":{"begin":549,"end":559},"obj":"Gene"},{"id":"337","span":{"begin":355,"end":365},"obj":"Species"},{"id":"338","span":{"begin":918,"end":933},"obj":"Species"},{"id":"339","span":{"begin":765,"end":778},"obj":"Chemical"},{"id":"340","span":{"begin":780,"end":784},"obj":"Chemical"},{"id":"341","span":{"begin":180,"end":199},"obj":"Disease"}],"attributes":[{"id":"A337","pred":"tao:has_database_id","subj":"337","obj":"Tax:2697049"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"Tax:9544"},{"id":"A341","pred":"tao:has_database_id","subj":"341","obj":"MESH:D003141"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}

{"project":"2_test","denotations":[{"id":"32519842-32259480-158492","span":{"begin":268,"end":270},"obj":"32259480"},{"id":"32519842-32259480-158493","span":{"begin":366,"end":368},"obj":"32259480"},{"id":"32519842-32376603-158494","span":{"begin":986,"end":988},"obj":"32376603"}],"text":"Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.27 All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.27 An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech’s, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in Science,71 and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608)."}